Cholestene lawsuit
This article was originally published in The Tan Sheet
Executive Summary
Cholestin-maker Pharmanex files civil contempt motion against HPF LLC, alleging the Trevose, Penn.-based firm's marketing of its Cholestene red yeast rice product violates a Utah federal judge's preliminary injunction. Pharmanex asserts HPF has continued to advertise Cholestene in its old trade dress, continued to rely on Cholestin-based studies in advertising, product materials and on the Internet. A hearing on the motion is set for Oct. 12. A trial is tentatively scheduled for November 2000 on Pharmanex's claims that Cholestene packaging is deceptively similar to Cholestin (1"The Tan Sheet" May 10, In Brief)
You may also be interested in...
Cholestene injunction
Salt Lake City, Utah federal court issues preliminary injunction against Prevose, Penn.-based HPF, Inc. in response to a complaint filed by Pharmanex, the Cholestin manufacturer says. Judge Dale Kimball orders that until the case comes to trial, Cholestene may not be marketed in its current packaging. The injunction follows an April 14 suit filed by Pharmanex asserting Cholestene packaging is deceptively similar to that of Cholestin. According to company data, Pharmanex has spent approximately $5 mil. on R&D for its red yeast rice dietary supplement for healthy cholesterol in addition to $1.8 mil. in litigation against FDA to protect the regulatory status of the product
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands